These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35868337)

  • 1. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies.
    Loesche M; Karlson EW; Talabi O; Zhou G; Boutin N; Atchley R; Loevinsohn G; Chang JBP; Hasdianda MA; Okenla A; Sampson E; Schram H; Magsipoc K; Goodman K; Donahue L; MacGowan M; Novack LA; Jarolim P; Baden LR; Nilles EJ
    Emerg Infect Dis; 2022 Sep; 28(9):1859-1862. PubMed ID: 35868337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study.
    Schaffner A; Risch L; Weber M; Thiel S; Jüngert K; Pichler M; Wohlwend N; Lung T; Ritzler M; Hillmann D; Copeland S; Renz H; Paprotny M; Risch M
    Clin Chem Lab Med; 2020 Nov; 59(2):e49-e51. PubMed ID: 33554502
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK.
    Shrotri M; Harris RJ; Rodger A; Planche T; Sanderson F; Mahungu T; McGregor A; Heath PT; ; Brown CS; Dunning J; Hopkins S; Ladhani S; Chand M
    Emerg Infect Dis; 2021 Apr; 27(4):1155-1158. PubMed ID: 33734962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
    Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF
    J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
    Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG
    J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trajectory and Demographic Correlates of Antibodies to SARS-CoV-2 Nucleocapsid in Recently Infected Blood Donors, United States.
    Haynes JM; Dodd RY; Crowder LA; Notari EP; Stramer SL
    Emerg Infect Dis; 2023 Jul; 29(7):1323-1329. PubMed ID: 37163762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleocapsid Antibody Versus Spike Protein Antibody: a Summative Analysis for Diagnosis of SARS-CoV-2 Infection at any Time.
    Tin SS; Wiwanitkit V
    Clin Lab; 2022 Mar; 68(3):. PubMed ID: 35254017
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests.
    De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S
    Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients.
    Yang L; Xu Q; Yang B; Li J; Dong R; Da J; Ye Z; Xu Y; Zhou H; Zhang X; Liu L; Zha Y; Yu F
    BMC Microbiol; 2021 Dec; 21(1):351. PubMed ID: 34922455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2.
    Dangi T; Class J; Palacio N; Richner JM; Penaloza MacMaster P
    Cell Rep; 2021 Sep; 36(10):109664. PubMed ID: 34450033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
    Terry JS; Anderson LB; Scherman MS; McAlister CE; Perera R; Schountz T; Geiss BJ
    Virology; 2021 Jun; 558():28-37. PubMed ID: 33714753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness.
    Sherwood LJ; Hayhurst A
    ACS Synth Biol; 2021 Feb; 10(2):379-390. PubMed ID: 33534552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
    Szymczak A; Jędruchniewicz N; Torelli A; Kaczmarzyk-Radka A; Coluccio R; Kłak M; Konieczny A; Ferenc S; Witkiewicz W; Montomoli E; Miernikiewicz P; Bąchor R; Dąbrowska K
    J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34816794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective.
    Li D; Li J
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33318065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.